Bank of Marin Buys 1,066 Shares of Johnson & Johnson (NYSE:JNJ)

Bank of Marin increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 60.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,815 shares of the company’s stock after buying an additional 1,066 shares during the quarter. Bank of Marin’s holdings in Johnson & Johnson were worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. IFS Advisors LLC grew its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $32,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $35,000. Activest Wealth Management purchased a new position in Johnson & Johnson during the 3rd quarter worth $40,000. Finally, NewSquare Capital LLC grew its stake in Johnson & Johnson by 145.8% during the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after buying an additional 172 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JNJ has been the topic of several research analyst reports. Barclays boosted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Citigroup cut their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Raymond James cut their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Finally, Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $164.24 on Wednesday. The company has a market capitalization of $395.80 billion, a P/E ratio of 24.70, a P/E/G ratio of 2.56 and a beta of 0.47. The business’s 50 day moving average is $155.73 and its two-hundred day moving average is $156.25. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 earnings per share. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.